Difference between revisions of "Medroxyprogesterone acetate (MPA)"
Jump to navigation
Jump to search
m |
m |
||
(4 intermediate revisions by the same user not shown) | |||
Line 5: | Line 5: | ||
*[[Breast cancer - historical|Breast cancer]] | *[[Breast cancer - historical|Breast cancer]] | ||
*[[Renal cell carcinoma - historical|Renal cell carcinoma]] | *[[Renal cell carcinoma - historical|Renal cell carcinoma]] | ||
+ | |||
+ | ==History of changes in FDA indication== | ||
+ | *1959-06-18: Initial approval | ||
+ | ==History of changes in EMA indication== | ||
+ | *1959-08-20: EURD | ||
==Also known as== | ==Also known as== | ||
Line 15: | Line 20: | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
− | [[Category: | + | [[Category:Progestins]] |
[[Category:Endometrial cancer medications]] | [[Category:Endometrial cancer medications]] | ||
Line 23: | Line 28: | ||
[[Category:FDA approved in 1959]] | [[Category:FDA approved in 1959]] | ||
− | + | [[Category:EMA approved in 1959]] | |
[[Category:Stub]] | [[Category:Stub]] |
Latest revision as of 10:42, 4 July 2023
Diseases for which it is used
Diseases for which it was used
History of changes in FDA indication
- 1959-06-18: Initial approval
History of changes in EMA indication
- 1959-08-20: EURD
Also known as
- Generic names: medroxyprogesterone acetate, MPA
- Brand names: Depo-Provera, Provera